Studies on the Mechanisms of Glucocorticoid Hypertension in Humans

References

• Gold E M. The Cushing syndromes: changing views of diagnosis and treatment. Ann Intern Med 1979; 90: 829–44
   PubMed Web of Science ®Google Scholar
• Bertagna X. New causes of Cushing's syndrome. N Engl J Med 1992; 327: 1024–5
   PubMedGoogle Scholar
• Armbruster H, Vetter W, Reck G, et al. Severe arterial hypertension caused by chronic abuse of a topical mineralocorticoid. Int J Clin Pharmacol Res 1975; 12: 170–3
   Google Scholar
• O'Sullivan M M, Rumfeld W R, Jones M K, Williams B D. Cushing's syndrome with suppression of the hypothalamic pituitary adrenal axis after intra-articular steroid injections. Ann Rheum Dis 1985; 44: 561–3
   PubMed Web of Science ®Google Scholar
• Smals A G, Kloppenborg P W, Njo K T, et al. Alcohol-induced Cushingoid syndrome. BMJ 1979; 2: 1–98
   PubMedGoogle Scholar
• Sugihara N, Shimizu M, Kita Y, et al. Cardiac characteristics and post-operative course in Cushing's syndrome. Am J Cardiol 1992; 69: 1475–80
   PubMedGoogle Scholar
• Plotz C, Knowlten A, Ragan C. The natural history of Cushing's syndrome. Am J Med 1952; 13: 597–614
   PubMed Web of Science ®Google Scholar
• Ross E J, Linch D C. Cushing's syndrome—killing disease. Discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; ii: 646–9
   Google Scholar
• Scoggins B A, Whitworth J A. Hypertension in Cushing's syndrome. Diseases of the kidney. 5th Ed, R W Schrier, C W Gottschalk. Little Brown & Co., Boston 1993; 1541–53
   Google Scholar
• Whitworth J A. Cushing's syndrome and hypertension. The Textbook of hypertension, J Swales. Blackwell Scientific Publications, Oxford 1994, (in press)
   Google Scholar
• Whitworth J A, Gordon D, Andrews J, Scoggins B A. The hypertensive effect of synthetic glucocorticoids in man: Role of sodium and volume. J Hypertens 1989; 7: 537–49
   PubMed Web of Science ®Google Scholar
• Connell J MC, Whitworth J A, Davies D L, Lever A F, Richards A M, Fraser R. Effects of ACTH and Cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 1987; 5: 425–33
   PubMed Web of Science ®Google Scholar
• Whitworth J A, Scoggins B A, Andrews J, Williamson P M, Brown M A. Haemodynamic and metabolic effects of short term administration of synthetic sex steroids in humans. Clin Exp Hypertens [A] 1992; 5: 905–22
   Google Scholar
• Whitworth J A, Saines D, Scoggins B A. Blood pressure and metabolic effects of Cortisol and deoxycorticosterone in man. Clin Exp Hypertens [A] 1984; 6: 795–809
   PubMed Web of Science ®Google Scholar
• Pirpiris M, Yeung S, Dewar E, Jennings G L, Whitworth J A. Hydrocortisone-induced hypertension in men: the role of cardiac output. Am J Hypertens 1993; 6: 287–94
   PubMed Web of Science ®Google Scholar
• Connell J MC, Whitworth J A, Inglis G C, Kenyon C J, Lever A F, Fraser R. Changes in body electrolytes, renal function, blood pressure and pressor responsiveness during development of ACTH and Cortisol excess in man. Corticosteroids and peptide hormones in hypertension, F Mantero, P Vescei, New York 1987; Vol. 39: 179–90, Serono Symposium
   Google Scholar
• Suzuki H, Shibata H, Muramaki M, Nakamoto H, Kondo K, Saruta T. Case report: hypertension in Cushing's syndrome. Am J Med Sci 1992; 303: 329–32
   PubMedGoogle Scholar
• Soszynski P, Slowinska-Srzednicka J, Kasberlik-Zaluska A, Zgliczynski S. Endogenous natriuretic factors: atrial natriuretic hormone and digitalis-like substance in Cushing's syndrome. J Endocrinol 1991; 129: 453–8
   PubMedGoogle Scholar
• Whitworth J A, Saines D, Thatcher R, Butkus A, Scoggins B A. Blood pressure and metabolic effects of ACTH in normotensive and hypertensive man. Clin Exp Hypertens [A] 1983; 5: 501–22
   PubMed Web of Science ®Google Scholar
• Schalekamp M ADH, Wenting G J, ManIn't Veld A J. Pathogenesis of mineralocorticoid hypertension. Clin Endocrinol Metab 1981; 10: 397
   PubMedGoogle Scholar
• Coleman T G, Granger H J, Guyton A C. Whole body circulatory auto-regulation and hypertension. Circ Res 1971; 28: 76–87
   PubMedGoogle Scholar
• Whitworth J A, Butkus A, Coghlan J P, Denton D A, Mills E H, Spence C D, Scoggins B A. 9α-flurocortisol-induced hypertension: a review. J Hypertens 1986; 4: 133–9
   PubMed Web of Science ®Google Scholar
• Pirpiris M, Sudhir K, Yeung S, Jennings G L, Whitworth J A. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19: 567–74
   PubMed Web of Science ®Google Scholar
• Haack D, Mohring J, Mohring B, Petri M, Hackenthal E. Comparative study on development of corticosterone and DOCA-hypertension in rats. Am J Physiol 1977; 233: F403
   PubMed Web of Science ®Google Scholar
• Schmid P G, Eckstein J W, Abboud F M. Effect of 9α-flurohydrocortisone on forearm vascular responses to norepinephrine. Circulation 1966; 34: 620–5
   PubMedGoogle Scholar
• Schmid P G, Eckstein J W, Abboud F M. Comparison of effects of deoxycorticosterone and dexamethasone on cardiovascular responses to norepinephrine. Circulation 1967; 46: 590–8
   Google Scholar
• Mendlowitz M, Naftchi N, Weinreb H L, Gitlow S E. Effect of prednisolone on the digital vascular reactivity in normotensive and hypertensive subjects. J Appl Physiol 1961; 16: 89–94
   PubMed Web of Science ®Google Scholar
• Mendlowitz M, Gitlow S E, Naftchi N. Work of digital vasoconstriction produced by infused norepinephrine in Cushing's syndrome. J Appl Physiol 1958; 13: 252–6
   PubMed Web of Science ®Google Scholar
• Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K, Senba S. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 1986; 62: 275–9
   PubMed Web of Science ®Google Scholar
• Whitworth J A, Connell J MC, Lever A F, Fraser R. Pressor responsiveness in steroid induced hypertension in man. Clin Exp Pharmacol Physiol 1986; 13: 353–8
   PubMed Web of Science ®Google Scholar
• Whitworth J A, Connell J MC, Gordon D, Scoggins B A. Effects of indomethacin on steroid induced changes in pressor responsiveness in man. Clin Exp Pharmacol Physiol 1988; 15: 305–10
   PubMed Web of Science ®Google Scholar
• Sudhir K, Jennings G L, Esler M D, et al. Hydrocortisone-induced hypertension in man: Pressor responsiveness and sympathetic function. Hypertension 1989; 13: 416–21
   PubMed Web of Science ®Google Scholar
• Rascher W, Dietz R, Schomig A, Burkart G, Luth J B, Mann J FE, Weber J. Modulation of sympathetic vascular tone by prostaglandins in corticosterone induced hypertension in rats. Clin Sci 1979; 57: S235–7
   PubMed Web of Science ®Google Scholar
• Axelrod L. Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Lancet 1983; i: 904–6
   Google Scholar
• Nakamura K, Gerald M, Thoenen H. Experimental hypertension of the rat: Reciprocal changes of norepinephrine turnover in heart and brain. Naunyn Schmiede-bergs Arch Pharmacol 1971; 268: 125–39
   PubMed Web of Science ®Google Scholar
• De Champlain J, Van Ameringan M R. Regulation of blood pressure by sympathetic nerve fibres in adrenal medulla in normotensive and hypertensive rats. Circ Res 1972; 31: 617–24
   PubMed Web of Science ®Google Scholar
• Li M, Whitworth J A. Role of the sympathetic nervous system in the onset of hypertension in the rat: The effect of 6-OH-dopamine. Clin Exp Pharmacol Physiol 1991; 18: 197–204
   PubMed Web of Science ®Google Scholar
• Ritchie C M, Sheridan B, Fraser R, et al. Studies on the pathogenesis of hypertension in Cushing's disease and acromegaly. Q J Med 1990; 280: 855–67
   Google Scholar
• Tenscher T W, Baumgart B, Greminger P, Vetter W, Vetter H. Pathogenetic aspects of hypertension in Cushing's syndrome. Cardiology 1985; 72: 184–90
   Google Scholar
• Morris M J, Russell A E, Kapoor V, Cain M D, Elliott J M, West M J, Wing L MH, Chalmers J P. Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J Auton Nerv Syst 1986; 17: 143–9
   PubMedGoogle Scholar
• Moreau P, de Champlain J, Yamaguchi N. Alterations in circulating levels and cardiovascular tissue content of neuropeptide Y-like immunoreactivity during the development of deoxycorticosterone acetate-salt hypertension in the rat. J Hypertens 1992; 10: 773–80
   PubMedGoogle Scholar
• Whitworth J A, Williamson P M, Brown M A, Morris M J. Neuropeptide Y in Cortisol induced hypertension in man, (Submitted)
   Google Scholar
• Fekete M I, Paldi-Haris P, Kenessey A, Graf L, Kanyieska B, Simonyi A. Effects of prolonged dexamethasone and ACTH treatment on the trypsin like and PNMT activity in the adrenals of the rat. Proceedings of the 8th International Congress of Pharmacology. 1981; 300
   Google Scholar
• Waeber B, Gavras H, Bresnaham M R, Gavras I, Brunner H R. Role of vasoconstrictor systems in experimental glucocorticoid hypertension in rats. Clin Sci 1983; 65: 255–61
   PubMed Web of Science ®Google Scholar
• Majewski H, Rand M J. Adrenaline mediated hypertension—a clue to the anti-hypertensive effect of β-adrenore-ceptor blocking drugs?. Trends Pharmacol Sci 1981; 2: 24
   Web of Science ®Google Scholar
• Li M, Birchall I, Kincaid-Smith P, Whitworth J A. Role of the renal medulla in adrenocorticotrophin-induced hypertension in rats. J Hypertens 1992; 10: 1129–36
   PubMedGoogle Scholar
• Rees D D, Palmer R MJ, Moncada S. Role of endothelium derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 3375–8
   PubMed Web of Science ®Google Scholar
• Li M, Dusting G J, Whitworth J A. Inhibition of NO synthesis has an additive effect on hypertension induced by ACTH in conscious rats. Clin Exp Pharmacol Physiol 1992; 19: 675–81
   PubMed Web of Science ®Google Scholar
• Yamaji T, Ishibashi M, Yamada A, Takaku F, Itabashi A, Katayama S, Ishi I J, Takami M, Fukushima T. Plasma levels of atrial natriuretic hormone in Cushing's syndrome. J Clin Endocrinol Metab 1988; 67: 348–52
   PubMedGoogle Scholar
• Krakoff L R, Selvadurai R, Sutter E. Effect of methyl-prednisolone upon arterial pressure in the renin-angiotensin system in the rat. Am J Physiol 1975; 228: 613–7
   PubMed Web of Science ®Google Scholar
• Okuno T, Suzuki H, Saruta T. Dexamethasone hypertension in rats. Clin Exp Hypertens [A] 1981; 3: 1075–86
   Google Scholar
• Elijovich F, Krakoff L R. Mechanism of the response to captopril in glucocorticoid hypertension. Clin Exp Hypertens [A] 1982; 4: 1795–814
   PubMed Web of Science ®Google Scholar
• Kohlmann O, Marson O, Ramos O, Ribeiro A. Effect of captopril on glucocorticoid excess hypertension. Clin Res 1980; 28: 333A
   Google Scholar
• Dalakos T G, Elias A N, Anderson G H, Streeten D H, Schroeder E T. Evidence for an angiotensinogenic mechanism of the hypertension of Cushing's syndrome. J Clin Endocrinol Metab 1978; 46: 114–8
   PubMed Web of Science ®Google Scholar
• Vetter W, Vetter H, Beckerhoff R, Redlich B, Cottier P, Siegenthaler W. The effect of saralasin (1-SAR-8-ALA-angiotensin II) on blood pressure in patients with Cushing's syndrome. Klin Wochenschr 1976; 54: 661–3
   PubMedGoogle Scholar
• Greminger P, Tenscher T TW, Vetter W, Luscher T, Vetter H. Hypertension in Cushing's syndrome. Endocrinology in hypertension, F Mantero, E G Biglieri, C RW Edwards. Academic Press, London, New York 1982; 103–10
   Google Scholar
• Mohring J, Mohring B, Petri M, Haack D. Vasopressin role of ADH in the pathogenesis of malignant DOC hypertension. Am J Physiol 1972; 232: F260
   Google Scholar
• Saito T, Yajima Y, Sato K. Evidence for the involvement of AVP in maintenance and development of hypertension in rats. Proceedings of the Sixth International Congress of Endocrinology. 1984; 24
   Google Scholar
• Ramos-Frendo B, Eloy L, Grunfeld J-P. Methylpredni-solone induced hypertension in the rat: evidence against the role of plasma volume changes, vasopressin and renal prostaglandin E2. J Hypertens 1985; 3: 461–7
   PubMed Web of Science ®Google Scholar
• Whitworth J A, Hewitson T D, Cornwallis C. Corticotro-phin effects on blood pressure and fluid and electrolyte homeostasis in five strains of rats. Am J Hypertens 1992; 5: 302–13
   PubMedGoogle Scholar
• Vane J. Endothelins come home to roost. Nature 1990; 348: 673
   PubMedGoogle Scholar
• Huang L Q, Whitworth J A, Chesterman C N. Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells, (Submitted)
   Google Scholar
• Jones A W, Hart R G. Altered ion transport in aortic smooth muscle during DOCA hypertension in the rat. Circ Res 1975; 37: 333
   PubMed Web of Science ®Google Scholar
• Haddy F J, Overbeck H W. The role of humoral agents in volume expanded hypertension. Life Sci 1976; 19: 935
   PubMed Web of Science ®Google Scholar
• Charney A N, Silva P, Besarab A, Epstein F H. Separate effects of aldosterone, DOCA and methylprednisolone on renal Na-KATP-ase. Am J Physiol 1974; 227: 345–50
   PubMed Web of Science ®Google Scholar
• Pamnani M B, Clough D L, Haddy F J. Altered activity of the sodium potassium pump in arteries of rats with steroid hypertension. Clin Sci Molecular Med 1978; 55: 41S–3
   PubMedGoogle Scholar
• Wambach G, Helber A, Allolio B, Winkelmann W, Kaufmann W. Increased activity of the Na-KATP-ase in red cell ghosts of patients with Cushing's syndrome: Possible significance of the pathogenesis of glucocorticoid induced hypertension. Klin Wochenschr 1980; 58: 485–7
   PubMedGoogle Scholar
• Graham W F, Campbell D J, Coghlan J P, Denton D A, Humphrey T J, Scoggins B A, Weisinger R S. Changes in the relationship between cerebro-spinal fluid and blood composition produced by ACTH treatment in conscious sheep. Life Sci 1980; 26: 2265–71
   PubMed Web of Science ®Google Scholar
• Brody M J, Fink G D, Buggy J, Haywood J R, Gordon F J, Johnson A K. The role of anteroventral third ventricle region in experimental hypertension. Circ Res 1978; 43: 12–13
   Google Scholar
• Buggy J, Fink G D, Johnson A K, Brody M J. Prevention of the development of renal hypertension by anteroventral third ventricular tissue lesions. Circ Res 1977; 40(5 Suppl 1)1110–7
   Google Scholar
• Meneely G R, Dahl L K. Electrolytes in hypertension: The effects of sodium chloride. The evidence from animal and human studies. Med Clin North Am 1961; 45: 271–83
   PubMed Web of Science ®Google Scholar
• Fallis N, Lasagne L, Tetreault L. Gustatory thresholds in patients with hypertension. Nature 1962; 196: 74–5
   Google Scholar
• Weisinger R S, Denton D A, McKinley M J, Nelson J F. ACTH induced sodium appetite in the rat. Pharmacol Biochem Behav 1978; 8: 339–42
   PubMed Web of Science ®Google Scholar
• Weisinger R S, Coghlan J P, Denton D A, et al. ACTH induced sodium appetite in sheep. Am J Physiol 1980; 239: E45–50
   PubMed Web of Science ®Google Scholar
• Scoggins B A, Coghlan J P, Denton D A, Whitworth J A. ACTH dependent hypertension. Clin Exp Hypertens [A] 1984; 6: 599–646
   PubMed Web of Science ®Google Scholar
• Whitworth J A, Hewitson T D, Wilson R S, et al. ACTH hypertension in the rat: Haemodynamic, metabolic and morphologic characteristics. J Hypertens 1990; 8: 27–36
   PubMed Web of Science ®Google Scholar
• Wong K S, Williamson P M, Brown M A, Zammit V C, Denton D A, Whitworth J A. Effects of Cortisol on blood pressure and salt preference in normal humans. Clin Exp Pharmacol Physiol 1993; 20: 121–6
   PubMed Web of Science ®Google Scholar
• Blaustein M P. Sodium ions, calcium ions, blood pressure regulation and hypertension. Am J Physiol 1977; 232: C165–73
   PubMed Web of Science ®Google Scholar
• DeWardener H E, McGregor G A. Dahl's hypothesis that a saluretic substance may be responsible for a sustained rise in arterial pressure: Its possible role in essential hypertension. Kidney Int 1980; 18: 1–9
   PubMed Web of Science ®Google Scholar
• Hamlyn J M, Ringel R, Schaeffer J, et al. A circulating inhibitor of sodium potassium ATP-ase associated with essential hypertension. Nature 1982; 300: 650–2
   PubMed Web of Science ®Google Scholar
• Spence C D, Coghlan J P, Whitworth J A, Scoggins B A. Digoxin enhances the pressor response to aldosterone administration in conscious sheep. Clin Exp Pharmacol Physiol 1989; 16: 211–22
   PubMedGoogle Scholar
• Garwitz E T, Jones A W. Aldosterone infusion into the rat and dose-dependent changes in blood pressure and arterial ionic transport. Hypertension 1982; 4: 374–381
   PubMed Web of Science ®Google Scholar
• Li M, Martin A, Liu D T, Whitworth J A. Digoxin amplifies the effects of DOCA in intact water drinking rats: implications for the mechanism of DOCA hypertension, (submitted)
   Google Scholar
• Sowers J R, Khoury S, Standley P, Zemel P, Zemel M. Mechanisms of hypertension in diabetes. Am J Hypertens 1991; 4: 177–82
   PubMed Web of Science ®Google Scholar
• Whitworth J A, Williamson P M, Brown M A, Coleman P. Hyperinsulinaemia as a mechanism for Cortisol induced hypertension, (submitted)
   Google Scholar
• Carretta R, Fabris B, Fischetti F, Costantini M, DeBiasi F, Muiesan S, Bardelli M, Vran F, Campanacci L. Reduction of blood pressure in obese, hyperinsulinemic, hypertensive patients during somatostatin infusion. J Hypertens 1989; 7: S196–7
   Google Scholar
• Scoggins B A, Coghlan J P, Denton D A, Mills E H, Nelson M A, Spence C D, Whitworth J A. How do adrenocortical steroid hormones produce hypertension?. Clin Exp Hypertens [A] 1984; 6: 315–28
   PubMed Web of Science ®Google Scholar
• Scoggins B A, Butkus A, Coghlan J P, Denton D A, Fan J SK, Humphrey T J, Whitworth J A. Adrenocorticotro-phic hormone induced hypertension in sheep: A model for the study of the effect of steroid hormones on blood pressure. Circ Res 1978; 43: 176–81
   Google Scholar
• Scoggins B A, Coghlan J P, Denton D A, Mason R T, Whitworth J A. A review of mechanisms involved in the production of steroid induced hypertension with particular reference to ACTH dependent hypertension. Endocrinology of hypertension, F Mantero, E G Biglieri, C RW Edwards. Academic Press, London and New York 1982; 41–67
   Google Scholar
• Whitworth J A, Coghlan J P, Denton D A, Graham W F, Humphery T J, Scoggins B A. Comparison of the effects of glucocorticoid and mineralocorticoid infusions on blood pressure in sheep. Clin Exp Hypertens [A] 1979; 1: 649–63
   Google Scholar
• Clore J N, Estep H, Ross-Clunis H, Watlington C O. Adrenocorticotrophin and Cortisol induced changes in urinary sodium and potassium excretion in man. Effects of spinolactone and RU-486. J Clin Endocrinol Metab 1988; 67: 824–31
   PubMedGoogle Scholar
• Coghlan J P, Denton D A, Mills E H, et al. Steroid antagonism of the hypertensinogenic activity of 9α-fluroprednisolone. Life Sci 1984; 35: 2609–12
   PubMed Web of Science ®Google Scholar
• Whitworth J A, Scoggins B A. A ‘hypertensinogenic’ class of steroid hormone activity in man?. Clin Exp Pharmacol Physiol 1990; 17: 163–6
   PubMed Web of Science ®Google Scholar
• Whitworth J A, Saines D, Thatcher R. Differential blood pressure and metabolic effects of 9α-flurocortisol in man. Clin Exp Pharmacol Physiol 1983; 10: 351–4
   PubMed Web of Science ®Google Scholar